title: Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?
abstract: BACKGROUND
  An increased risk for impaired glucose tolerance or diabetes was shown in patients on beta-blockers, whereas alpha1 blockers seem to have favorable effects on glycemic profile. In this study, the metabolic effect of carvedilol in nondiabetic patients with chronic heart failure (CHF) was evaluated.
  
  
  RESULTS
  Twenty-eight nondiabetic CHF patients were enrolled. Before being started on carvedilol and on the highest tolerated dose, each patient underwent an oral glucose tolerance test and fasting insulin, glycohemoglobin, lipid concentrations were measured and insulin sensitivity indices (HOMA, ISI-gly, and ISI-composite) were calculated. An impaired glucose tolerance was found (2-hour glycemia 144 +/- 42 mg/dL), with a fasting glycemia at upper limits of normal (108 +/- 13 mg/dL) and no significant differences between basal and carvedilol treatment measurements. Fasting insulinemia significantly decreased during carvedilol treatment (13.6 +/- 7.3 versus 9.8 +/- 5.1 muU/mL; P = .022), with a reduction of the HOMA index (3.75 +/- 1.95 versus 2.73 +/- 1.47; P = 034) and an increase of the ISI-gly index (0.85 +/- 0.22 versus 1.03 +/- 0.31; P = .025). The lipoprotein profile did not significantly change.
  
  
  CONCLUSIONS
  Carvedilol might have some positive metabolic effects on increasing insulin sensitivity that would make it suitable for diabetic patients that have a worse prognosis than non diabetic patients with CHF.
authors.affiliation: University Department of Cardiology, San Giovanni Battista Hospital, Turin, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Ferrua
authors.forename: Marco
authors.initials: M
authors.lastname: Bobbio
authors.forename: Elisa
authors.initials: E
authors.lastname: Catalano
authors.forename: Giorgio
authors.initials: G
authors.lastname: Grassi
authors.forename: Nicola
authors.initials: N
authors.lastname: Massobrio
authors.forename: Silvia
authors.initials: S
authors.lastname: Pinach
authors.forename: Claudio
authors.initials: C
authors.lastname: Rossi
authors.forename: Massimo
authors.initials: M
authors.lastname: Veglio
authors.forename: Gian Paolo
authors.initials: GP
authors.lastname: Trevi
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002227:Carbazoles / Q000008:administration & dosage / Q000009:adverse effects*; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D005215:Fasting / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000008:administration & dosage / Q000009:adverse effects*; D012107:Research Design; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000319:Adrenergic beta-Antagonists; D015415:Biomarkers; D001786:Blood Glucose; D002227:Carbazoles; D007328:Insulin; D011412:Propanolamines; D000077261:Carvedilol